MYL - Mylan N.V.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
38.94
-1.31 (-3.25%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close40.25
Open40.08
Bid38.96 x 100
Ask39.93 x 300
Day's Range38.45 - 40.15
52 Week Range29.39 - 47.82
Volume5,804,163
Avg. Volume4,720,859
Market Cap20.046B
Beta1.33
PE Ratio (TTM)29.95
EPS (TTM)1.30
Earnings DateMay 8, 2018 - May 14, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend Date2007-06-27
1y Target Est49.86
Trade prices are not sourced from all markets
  • How Analysts Rate Bristol-Myers Squibb in 1Q18
    Market Realist13 hours ago

    How Analysts Rate Bristol-Myers Squibb in 1Q18

    Wall Street analysts estimate Bristol-Myers Squibb’s top line to rise 6.5% to ~$5.2 billion in 1Q18. Also, the earnings per share are expected at $0.85 for 1Q18. The revenue growth is expected to be driven by the prioritized brands including Opdivo, Empliciti, Eliquis, Orencia, Sprycel, and Yervoy, partially offset by lower sales of established brands.

  • How Johnson & Johnson’s Medical Devices Segment Performed in 1Q18
    Market Realist17 hours ago

    How Johnson & Johnson’s Medical Devices Segment Performed in 1Q18

    Johnson & Johnson’s (JNJ) medical devices business includes cardiovascular care products, orthopedics products, surgery products, vision care products, and diabetes products. The medical devices business reported 7.5% growth in revenues to $6.8 billion during 1Q18 as compared to revenues of $6.3 billion during 1Q17. The growth includes 3.2% growth in revenues at constant exchange rates and a 4.3% increase due to the positive impact of foreign exchange.

  • Mylan Adds to Growing Women's Healthcare Portfolio with Launch of Generic for Oral Contraceptive Yaz®
    PR Newswire17 hours ago

    Mylan Adds to Growing Women's Healthcare Portfolio with Launch of Generic for Oral Contraceptive Yaz®

    HERTFORDSHIRE, England and PITTSBURGH, April 25, 2018 /PRNewswire/ -- Global pharmaceutical company Mylan N.V. (MYL) today announced the U.S. launch of Drospirenone and Ethinyl Estradiol Tablets USP, 3 mg/0.02 mg, a generic version of Bayer's Yaz® Tablets. Mylan Pharmaceuticals received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for this product, which is indicated for use by women to prevent pregnancy and for the treatment of acne vulgaris in women at least 14 years of age who have achieved menarche and desire an oral contraceptive for birth control. In the U.S., Mylan offers more than 20 generic birth control medicines in multiple dosage forms.

  • Reutersyesterday

    Generic drugmakers to face first charges in U.S. probe - Bbg

    U.S. prosecutors were nearing their first charges against generic-drug companies in a nearly four-year-old criminal probe into a possible price-fixing, Bloomberg reported, citing people familiar with the matter. Soaring drug prices from both branded and generic drugmakers have sparked outrage and investigations in the past, with President Donald Trump last year calling it "getting away with murder". In October, Reuters reported https://www.reuters.com/article/us-usa-generics/u-s-states-allege-broad-generic-drug-price-fixing-collusion-idUSKBN1D0201 a lawsuit on the price-fixing case accused 18 companies, including Mylan and Teva Pharmaceutical, and named 15 medicines.

  • Generic-Drug Companies to Face First Charges in U.S. Probe
    Bloombergyesterday

    Generic-Drug Companies to Face First Charges in U.S. Probe

    U.S. prosecutors are nearing their first charges against companies in an almost four-year-old criminal investigation into alleged price-fixing by generic-drug makers, according to people familiar with ...

  • MarketWatch2 days ago

    Wegmans EpiPens out of stock, but no U.S. shortage currently seen, FDA says

    In spite of reports that Wegmans pharmacies are out of stock of the EpiPen allergic reaction treatment, the Food and Drug Administration is not currently aware of any U.S. shortage, though the regulator continues to monitor the supply, spokesperson Lauren Smith Dyer. Pfizer , which manufactures the Mylan product through one of its business units, said that it is currently shipping products but supplies may vary from pharmacy to pharmacy.

  • American City Business Journals3 days ago

    Mylan to lay off hundreds in West Virginia

    It's one of the state's largest employers.

  • Mylan Presents Equivalence Data on Glatiramer Acetate Compared to Copaxone® at American Academy of Neurology 70th Annual Meeting
    PR Newswire5 days ago

    Mylan Presents Equivalence Data on Glatiramer Acetate Compared to Copaxone® at American Academy of Neurology 70th Annual Meeting

    Three posters highlight Mylan's rigorous Glatiramer Acetate development program HERTFORDSHIRE, England , and PITTSBURGH , April 21, 2018 /PRNewswire/ -- Global pharmaceutical company Mylan N.V. (NASDAQ: ...

  • Reuters5 days ago

    Mylan cuts 15 pct of workforce at West Virginia plant

    Generic drugmaker Mylan NV on Friday announced layoffs of about 15 percent of its workforce at a pharmaceutical manufacturing plant in Morgantown, West Virginia. The company, which had faced intense criticism and political scrutiny over price hikes for its life-saving EpiPen emergency allergy treatment, said the Morgantown plant "needed to be rightsized to be less complex" for continued operations. The layoffs involved more than 400 employees represented by a United Steel Workers local union, reported WAJR, a Morgantown radio station.

  • Reuters8 days ago

    Canada seeks U.S. help to solve EpiPen shortage

    Canada said on Tuesday it is working with the U.S. Food and Drug Administration to access supplies of Mylan N.V.'s EpiPen emergency allergy antidote amid a growing shortage that has spared the United States. EpiPens deliver a potentially lifesaving dose of the generic drug epinephrine via an automatic injector. Last week, Pfizer notified consumers in Canada and Britain that the device is in short supply due to manufacturing problems.

  • Investopedia8 days ago

    7 Stock Picks With Giant Upside: Goldman

    Green Pastures: DISH, AbbVie, Hasbro and other stocks are poised to flourish

  • Pfizer Inc. Stock Has a Great Storyline That’s Not Panning Out
    InvestorPlace9 days ago

    Pfizer Inc. Stock Has a Great Storyline That’s Not Panning Out

    At first glance, Pfizer Inc. (NYSE:PFE) appears a worthwhile contrarian trade. Additionally, the overall markets have been soft, allowing shrewd investors to pick up PFE stock at a more attractive valuation. As a result, many analysts are questioning whether Pfizer stock, at its present cost, is worth the risk.

  • EpiPen shortages seen in Canada, UK but U.S. supply intact
    Reuters12 days ago

    EpiPen shortages seen in Canada, UK but U.S. supply intact

    By Bill Berkrot NEW YORK (Reuters) - Mylan N.V.'s emergency allergy antidote EpiPen is in short supply in Canada and Britain, but remains available in the United States, the treatment's manufacturer said on Friday. EpiPens deliver potentially lifesaving doses of the generic drug epinephrine, via an automatic injector that a patient or caregiver can administer in the event of severe allergic reaction. Currently there is no shortage in the U.S.," said Steve Danehy, a spokesman for Pfizer Inc , which produces the global supply of EpiPens for Mylan out of a single facility near St. Louis, Missouri.

  • Reuters12 days ago

    EpiPen shortages seen in Canada, UK but U.S. supply intact

    Mylan N.V.'s emergency allergy antidote EpiPen is in short supply in Canada and Britain, but remains available in the United States, the treatment's manufacturer said on Friday. EpiPens deliver potentially lifesaving doses of the generic drug epinephrine, via an automatic injector that a patient or caregiver can administer in the event of severe allergic reaction. Currently there is no shortage in the U.S.," said Steve Danehy, a spokesman for Pfizer Inc , which produces the global supply of EpiPens for Mylan out of a single facility near St. Louis, Missouri.

  • Mylan Denies Report It's Interested In Buying Merck KGaA's Consumer Biz
    Investor's Business Daily12 days ago

    Mylan Denies Report It's Interested In Buying Merck KGaA's Consumer Biz

    Mylan denied reports Friday that it's interested in buying Merck KGaA's consumer health care business, after Reckitt Benckiser and Nestle reportedly dumped their bids.

  • Mylan seeks deal for German Merck's consumer products unit: sources
    Reuters12 days ago

    Mylan seeks deal for German Merck's consumer products unit: sources

    FRANKFURT/NEW YORK (Reuters) - Generic drug maker Mylan NV is in advanced discussions to acquire Merck KGaA's consumer health business after other bidders failed to meet the German company's price expectations, people familiar with the matter said. "Although it's Mylan's policy to not comment on rumors or speculation, given the egregious inaccuracy of reports issued this morning, the company is compelled to confirm that the Reuters article is untrue," Mylan said in a statement on Friday. A Mylan spokeswoman declined to offer details on what in the Reuters story was inaccurate.

  • Mylan seeks deal for German Merck's consumer products unit - sources
    Reuters12 days ago

    Mylan seeks deal for German Merck's consumer products unit - sources

    FRANKFURT/NEW YORK (Reuters) - Generic drug maker Mylan NV is in advanced discussions to acquire Merck KGaA's consumer health business after other bidders failed to meet the German company's price expectations, people familiar with the matter said. "Although it's Mylan's policy to not comment on rumours or speculation, given the egregious inaccuracy of reports issued this morning, the company is compelled to confirm that the Reuters article is untrue," Mylan said in a statement on Friday. A Mylan spokeswoman declined to offer details on what in the Reuters story was inaccurate.

  • Merck KGaA Consumer Unit Is a Deal Too Far for Mylan
    Bloomberg12 days ago

    Merck KGaA Consumer Unit Is a Deal Too Far for Mylan

    The drugmaker isn't in a position to take on a lot more debt.

  • ACCESSWIRE13 days ago

    Wired News - Mylan to Collaborate with Fujifilm Kyowa Kirin Biologics for Commercializing Biosimilar to Humira(R) (adalimumab)

    Stock Monitor: SteadyMed Post Earnings Reporting LONDON, UK / ACCESSWIRE / April 13, 2018 / Active-Investors.com has just released a free research report on Mylan N.V. (NASDAQ: MYL ). If you want access ...

  • Mylan Fujifilm Kyowa Team Up to Market Humira Biosimilar
    Zacks13 days ago

    Mylan Fujifilm Kyowa Team Up to Market Humira Biosimilar

    Mylan (MYL) is partnering with Fujifilm Kyowa to commercialize a biosimilar to Humira (adalimumab).

  • Analyst Urges Investors To Buy This Drugmaker's Dip — And They Do
    Investor's Business Daily13 days ago

    Analyst Urges Investors To Buy This Drugmaker's Dip — And They Do

    Mylan shares rebounded Thursday following worries that first-quarter sales would lag based on tough comparisons for allergy drug EpiPen.

  • TheStreet.com13 days ago

    Mylan's Stock Gets Bump After Investor Day

    Following Wednesday's event, Leerink analyst Ami Fadia said she is 'incrementally more positive' on the drugmaker's pipeline and diversified business model and moved her rating to outperform.

  • MARKETS: Wall Street's biggest fear is a trade war and FAANG+BAT is still the most crowded trade
    Yahoo Finance Video9 days ago

    MARKETS: Wall Street's biggest fear is a trade war and FAANG+BAT is still the most crowded trade

    Yahoo Finance's Jared Blikre and Alexis Christoforous break down the latest market action.

  • MARKETS: Here's the line in the equity sand bulls must defend
    Yahoo Finance Video12 days ago

    MARKETS: Here's the line in the equity sand bulls must defend

    Yahoo Finance's Jared Blikre joins Seana Smith from the New York Stock Exchange to discuss the latest market moves.

  • Mylan CEO on rising drugs prices in the U.S.
    Yahoo Finance Video13 days ago

    Mylan CEO on rising drugs prices in the U.S.

    Drug prices are a top issue for Americans, and President Trump pledged to cut high drug costs throughout the beginning of his presidency. Heather Bresch, CEO of Mylan, talks with Yahoo Finance's Seana Smith and Andy Serwer.